Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders

 
 

Prevail Therapeutics Inc. (PRVL) Add to portfolio

1m | 3m | 6m | 1y | 2y | 5y | 10y
Price: $15.40 Metrics
OS: 34.2 M -48 % ROE
Market cap: $527 M -470 % ROIC
Net cash: $150 M $4.37 per share
EV: $377 M

 
TTM Valuation
EBITDA ($74.4) M
EBIT ($74.8) M
EPS ($2.38)

Recent News + Filings   (All items)

Financial Summary   (All financials)
In millions, except per share itemsDec-31-19Dec-31-18
Revenues0.00.1
            Revenue growth-100.0% 
Cost of goods sold0.00.1
Gross profit0.00.0
            Gross margin 0.0%
Research and development48.814.1
General and administrative17.04.7
EBIT-65.8-18.8
            EBIT margin -21619.5%
Pre-tax income-63.2-19.1
Income taxes0.00.0
            Tax rate0.0%0.0%
Net income-63.2-19.1
            Net margin -21939.1%
 
Diluted EPS($2.22)($3.71)
Shares outstanding (diluted)28.55.1
 
EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges.

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy